Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on nuclear factor erythroid 2-related factor 2 and mitochondrial biogenesis pathways
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
22915767
DOI
10.1124/jpet.112.198358
PII: S0022-3565(24)18418-2
Knihovny.cz E-zdroje
- MeSH
- antracykliny toxicita MeSH
- buněčné jádro účinky léků metabolismus MeSH
- daunomycin farmakologie MeSH
- echokardiografie MeSH
- faktor 2 související s NF-E2 biosyntéza MeSH
- funkční vyšetření srdce MeSH
- glutathion metabolismus MeSH
- králíci MeSH
- kvantitativní polymerázová řetězová reakce MeSH
- myokard patologie MeSH
- nemoci srdce chemicky indukované metabolismus MeSH
- oxidační stres účinky léků MeSH
- peroxidace lipidů účinky léků MeSH
- přežití MeSH
- protinádorová antibiotika toxicita MeSH
- srdeční komory účinky léků metabolismus MeSH
- srdeční mitochondrie účinky léků metabolismus MeSH
- transkripční faktory metabolismus MeSH
- troponin T metabolismus MeSH
- zvířata MeSH
- Check Tag
- králíci MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- antracykliny MeSH
- daunomycin MeSH
- faktor 2 související s NF-E2 MeSH
- glutathion MeSH
- peroxisome-proliferator-activated receptor-gamma coactivator-1 MeSH Prohlížeč
- protinádorová antibiotika MeSH
- transkripční faktory MeSH
- troponin T MeSH
Anthracycline anticancer drugs (e.g., doxorubicin or daunorubicin) can induce chronic cardiotoxicity and heart failure (HF), both of which are believed to be based on oxidative injury and mitochondrial damage. In this study, molecular and functional changes induced by chronic anthracycline treatment with progression into HF in post-treatment follow-up were analyzed with special emphasis on nuclear factor erythroid 2-related factor 2 (Nrf2) and peroxisome proliferator-activated receptor-γ coactivator-1α (PGC1α) pathways. Chronic cardiotoxicity was induced in rabbits with daunorubicin (3 mg/kg, weekly for 10 weeks), and the animals were followed for another 10 weeks. Echocardiography revealed a significant drop in left ventricular (LV) systolic function during the treatment with marked progression to LV dilation and congestive HF in the follow-up. Although daunorubicin-induced LV lipoperoxidation was found, it was only loosely associated with cardiac performance. Furthermore, although LV oxidized glutathione content was increased, the oxidized-to-reduced glutathione ratio itself remained unchanged. Neither Nrf2, the master regulator of antioxidant response, nor the majority of its target genes showed up-regulation in the study. However, down-regulation of manganese superoxide dismutase and NAD(P)H dehydrogenase [quinone] 1 were observed together with heme oxygenase 1 up-regulation. Although marked perturbations in mitochondrial functions were found, no induction of PGC1α-controlled mitochondrial biogenesis pathway was revealed. Instead, especially in the post-treatment period, an impaired regulation of this pathway was observed along with down-regulation of the expression of mitochondrial genes. These results imply that global oxidative stress need not be a factor responsible for the development of anthracycline-induced HF, whereas suppression of mitochondrial biogenesis might be involved.
Citace poskytuje Crossref.org